Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA Positive and Genotype 1b~* No history or signs or symptoms of decompensated liver disease or hepatocellular carcinoma within 6 months~* A patient who is on dialysis, or if not MDRD eGFR\<30ml/min~* HCV treatment history: HCV treatment-naive participants, defined as never having received HCV treatment with any approved or investigational drug (including vaccines); OR HCV treatment-experienced, defined as having received previous HCV treatment with any (pegylated) interferon (\[Peg\]IFN)-based drug regimen (with or without ribavirin \[RBV\] and not including a direct-acting antiviral agent \[DAA\]). Last dose in this previous HCV treatment course should have occurred at least 2 months prior to screening~* No baseline mutation NS5A polymorphism including L31F/I/M/V and Y93H~Exclusion Criteria:~* A patient who having received Daclatasvir or Asunaprevir~* Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study~* Evidence of a medical condition contributing to chronic liver disease other than HCV or seropositive for HIV~* Diagnosed or suspected hepatocellular carcinoma or other malignancies~* Any history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage)~* Received solid organ or bone marrow transplant~* Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance~* Significant renal, cardiovascular, pulmonary, or neurological disease and uncontrolled diabetes or hypertension in the opinion of the investigator~* Known hypersensitivity to study drugs, metabolites, or formulation excipients~* Who has taken investigational drugs within 2 months.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daclatasvir plus Asunaprevir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).